AI CuratorAI-generated
Research summary · AI summary · not yet reviewedSubjects not reportedInterventionalTrial registry record – peer review not applicable
P-CD19CD20-ALLO1 Cells in Animal Studies for Multiple Sclerosis
This study aims to assess the safety and tolerability of P-CD19CD20-ALLO1 cells, along with Cyclophosphamide and Fludarabine, in participants with progressive and relapsing multiple sclerosis. It focuses on dose-limiting toxicities over a follow-up period from Day 1 to Day 29.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
This plain-English summary was written by AI from a trial registry record and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Not yet assessed
- Mechanism
- Not yet assessed
- Evidence strength
- Not yet assessed
- Outcome
- Not yet assessed
Why it matters
Understanding the safety and pharmacodynamics of these treatments may inform future therapies for multiple sclerosis, potentially improving patient outcomes.
What this does not prove
No results were posted, and the planned endpoints do not reflect findings. Causation cannot be determined from the described study design.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Interventional
- Participants / samples
- 60 · estimated
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- All
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Yes
- Research areas
- Not classified
Original sources
Supporting passages (11)
sample size"count": 60
sample size basis"type": "ESTIMATED"
regulatory approval"isFdaRegulatedDrug": true
study design"studyType": "INTERVENTIONAL"
regulatory approval details"isFdaRegulatedDrug": true
relevant ms types"facility": "Multiple Sclerosis Comprehensive Care Center at Northwell Health",
intervention"interventionNames": [ "Biological: P-CD19CD20-ALLO1 Cells", "Drug: Cyclophosphamide", "Drug: Fludarabine" ]
primary endpoint"measure": "Number of Participants With Dose-limiting Toxicity (DLTs) at Each Dose Level of P-CD19CD20-ALLO1"
follow up"timeFrame": "Day 1 up to Day 29"
findings"briefSummary": "This study aims to explore the safety, tolerability, cellular kinetics, and pharmacodynamics of P-CD19CD20-ALLO1 in participants with progressive multiple sclerosis (PMS) and relapsing multiple sclerosis (RMS)."
limitationsPlanned enrolment and endpoints are not findings.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.